Abstract
The results of experiments in dogs with and without two glucose loads and in the isolated pancreas to compare the pharmacodynamics of two low-dosage aryl-sulphonylureas, glipizide and glibenclamide, are described and discussed. — The results agree with those obtained by other authors confirming that glibenclamide shows delayed but prolonged activity on both plasma insulin and glucose levels. Moreover glibenclamide counteracts the hyperglycaemia induced by the second glucose load less efficently. Glipizide acts faster on insulin and glucose levels, which return quickly to normal. When a second glucose load was given it was still more active in reducing plasma glucose levels. The dynamics of insulin secretion following glipizide more closely resembles tolbutamide than glibenclamide.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
